Pluri Inc. (PLUR) Discusses Commercialization Strategy, ZEO ScientifiX Transaction and Financial Flexibility Transcript
Pluri Inc. faces a precarious financial outlook characterized by erratic revenue streams and a rapid depletion of its liquidity buffer. The company's pivot toward CDMO services has yet to demonstrate scalability, as evidenced by the persistent inability to achieve positive operating margins.
Price trend, volume and key moving averages
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q1 2026Latest Feb 12, 2026 | -$0.71-9.2% vs -$0.65 | $198,000-69.0% vs $638,000 |
Q4 2025 Nov 12, 2025 | -$0.65+12.2% vs -$0.74 | $316,000-50.5% vs $638,000 |
Q4 2025 Sep 17, 2025 | -$2.62-303.1% vs -$0.65 | $398,000-37.6% vs $638,000 |
Q2 2025 May 13, 2025 | -$0.94-28.8% vs -$0.73 | $427,000+6.8% vs $400,000 |
Pluri Inc. (PLUR) Discusses Commercialization Strategy, ZEO ScientifiX Transaction and Financial Flexibility Transcript
Established U.S. commercial platform: ZEO contributes biologics manufacturing, scientific expertise, an existing product portfolio, physician relationships, and dedicated sales, marketing, and educational resources. Complementary technology and development capabilities: Pluri brings extensive experience in cell-based product development, clinical experience extending through Phase III trials and scalable manufacturing methods and expertise developed through its proprietary 3D cell-expansion platform.
HAIFA, Israel and EDINBURGH, Scotland, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Ever After Foods (EAF) and Roslin Technologies today announced results from their joint cultivated meat production program. Combining Roslin Technologies' advanced cell platform with Ever After Foods' proprietary Edible Packed Bed (EPB™) technology, the companies demonstrated substantial gains in protein and biomass productivity while producing structured tissue directly within a scalable and food-grade process.
Pluri (NASDAQ: PLUR - Get Free Report) is expected to post its results after the market closes on Wednesday, September 23rd. Analysts expect the company to announce earnings of ($0.66) per share and revenue of $0.6550 million for the quarter. Pluri (NASDAQ: PLUR - Get Free Report) last released its earnings results on Thursday, September 10th. The
Benchmark PLUR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Pluri Inc. (PLUR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.98 | $8.81M | -0.25 | -23.95% | -2265.14% | — | — | |
| $1.02 | $118.89M | -1.01 | -51.24% | -2619.64% | -73.92% | — | |
| $9.78 | $1.1B | -3.22 | 16.92% | -805.75% | -64.73% | — | |
| $20.65 | $2.12B | -20.19 | 120.01% | -73.04% | -9.69% | — | |
| $1.83 | $280.84M | -3.89 | 25.39% | -144.95% | -130.43% | — | |
| $40.15 | $3.87B | -8.52 | -89.97% | -1812.07% | -25.59% | — |
Pluri Inc. (PLUR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Pluri Inc. (PLUR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 28, 2026·SEC
Aug 17, 2026·SEC
Mar 27, 2026·SEC
Get notified when PLUR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Pluri Inc. (PLUR) stock FAQ — growth, dividends, profitability & financials explained
Pluri Inc. (PLUR) reported $2.1M in revenue over the trailing twelve months. Revenue was $1.0M in fiscal year 2026.
Pluri Inc. (PLUR) grew revenue by 61.4% over the trailing twelve months, compared with the twelve months before.
No. Pluri Inc. (PLUR) reported a net loss of $48.5M over the trailing twelve months.
Pluri Inc. (PLUR) had negative free cash flow of $19.2M over the trailing twelve months.